Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-((s)-2-azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)ethylamino)quinazoline-8-carboxylic Acid Amide
2. M2698
1. M2698
2. 1379545-95-5
3. Msc2363318a
4. 0dxg50i4wd
5. Chembl4871106
6. M-2698
7. Msc-2363318a
8. 1379545-95-5 (free Base)
9. (s)-4-((2-(azetidin-1-yl)-1-(4-chloro-3-(trifluoromethyl)phenyl)ethyl)amino)quinazoline-8-carboxamide
10. 4-({(1s)-2-(azetidin-1-yl)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl}amino)quinazoline-8-carboxamide
11. 8-quinazolinecarboxamide, 4-(((1s)-2-(1-azetidinyl)-1-(4-chloro-3-(trifluoromethyl)phenyl)ethyl)amino)-
12. 4-[[(1s)-2-(azetidin-1-yl)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]amino]quinazoline-8-carboxamide
13. Unii-0dxg50i4wd
14. Schembl15262358
15. Bcp19488
16. Ex-a1187
17. Bdbm50574277
18. Nsc795142
19. Db15431
20. Nsc-795142
21. Ac-36831
22. Hy-100501
23. Cs-0019628
24. M2698(msc-2363318a)
25. M-2698;m 2698; Msc-2363318a; Msc 2363318a; Msc2363318a
26. 1sk
| Molecular Weight | 449.9 g/mol |
|---|---|
| Molecular Formula | C21H19ClF3N5O |
| XLogP3 | 3.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Exact Mass | 449.1230224 g/mol |
| Monoisotopic Mass | 449.1230224 g/mol |
| Topological Polar Surface Area | 84.1 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 635 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Rupitasertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rupitasertib, including repackagers and relabelers. The FDA regulates Rupitasertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rupitasertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Rupitasertib supplier is an individual or a company that provides Rupitasertib active pharmaceutical ingredient (API) or Rupitasertib finished formulations upon request. The Rupitasertib suppliers may include Rupitasertib API manufacturers, exporters, distributors and traders.
Rupitasertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rupitasertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rupitasertib GMP manufacturer or Rupitasertib GMP API supplier for your needs.
A Rupitasertib CoA (Certificate of Analysis) is a formal document that attests to Rupitasertib's compliance with Rupitasertib specifications and serves as a tool for batch-level quality control.
Rupitasertib CoA mostly includes findings from lab analyses of a specific batch. For each Rupitasertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rupitasertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Rupitasertib EP), Rupitasertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rupitasertib USP).
LOOKING FOR A SUPPLIER?
